Table 1.

Characteristics of study participants and nonparticipants




Participants, no. (%)

Nonparticipants, no. (%)

P
Sex    .007  
   Female   264 (45.2)   148 (36.7)   
   Male   320 (54.8)   255 (63.3)   
Race/ethnicity    .005  
   White   449 (76.9)   270 (67.0)   
   Hispanic   79 (13.5)   81 (20.1)   
   Other   56 (9.6)   52 (12.9)   
Institution    .24  
   COH   304 (52.1)   193 (47.9)   
   UMN   280 (47.9)   210 (52.1)   
Age at transplantation*    < .001  
   Younger than 21 y   134 (22.9)   133 (33.0)   
   21-45 y   293 (50.2)   244 (60.5)   
   Older than 45 y   157 (26.9)   26 (6.5)   
Age at interview    < .001  
   18-45 y   374 (64.0)   312 (77.4)   
   Older than 45 y   210 (36.0)   91 (22.6)   
Time since transplantation    < .001  
   2-5 y   209 (35.8)   99 (24.6)   
   6-10 y   169 (28.9)   106 (26.3)   
   11-28 y   206 (35.3)   198 (49.1)   
Year of transplantation    .08  
   1975-1984   94 (16.1)   92 (22.8)   
   1985-1994   283 (48.5)   184 (45.7)   
   1995-2000   207 (35.4)   127 (31.5)   
Diagnosis    .006  
   Aplastic anemia   56 (9.6)   72 (17.9)   
   Acute leukemia   248 (42.5)   186 (46.1)   
   Lymphoma   44 (7.5)   16 (4.0)   
   Immune disorder   4 (0.7)   2 (0.5)   
   Chronic leukemia   230 (39.4)   122 (30.3)   
   Other   2 (0.3)   5 (1.2)   
Stem cell source    .24  
   Bone marrow   546 (93.5)   386 (95.8)   
   Cord blood   5 (0.9)   2 (0.5)   
   Peripheral blood stem cells   33 (5.7)   15 (3.7)   
Donor type    .004  
   Related   478 (81.8)   350 (86.6)   
   Unrelated   106 (18.2)   53 (13.2)   
Conditioning regimen    .02  
   Chemotherapy   55 (9.4)   57 (14.1)   
   Radiation and chemotherapy   529 (90.6)   346 (85.9)   
cGVHD    .04  
   Yes   313 (53.6)   188 (46.7)   
   No
 
271 (46.4)
 
215 (53.3)
 

 



Participants, no. (%)

Nonparticipants, no. (%)

P
Sex    .007  
   Female   264 (45.2)   148 (36.7)   
   Male   320 (54.8)   255 (63.3)   
Race/ethnicity    .005  
   White   449 (76.9)   270 (67.0)   
   Hispanic   79 (13.5)   81 (20.1)   
   Other   56 (9.6)   52 (12.9)   
Institution    .24  
   COH   304 (52.1)   193 (47.9)   
   UMN   280 (47.9)   210 (52.1)   
Age at transplantation*    < .001  
   Younger than 21 y   134 (22.9)   133 (33.0)   
   21-45 y   293 (50.2)   244 (60.5)   
   Older than 45 y   157 (26.9)   26 (6.5)   
Age at interview    < .001  
   18-45 y   374 (64.0)   312 (77.4)   
   Older than 45 y   210 (36.0)   91 (22.6)   
Time since transplantation    < .001  
   2-5 y   209 (35.8)   99 (24.6)   
   6-10 y   169 (28.9)   106 (26.3)   
   11-28 y   206 (35.3)   198 (49.1)   
Year of transplantation    .08  
   1975-1984   94 (16.1)   92 (22.8)   
   1985-1994   283 (48.5)   184 (45.7)   
   1995-2000   207 (35.4)   127 (31.5)   
Diagnosis    .006  
   Aplastic anemia   56 (9.6)   72 (17.9)   
   Acute leukemia   248 (42.5)   186 (46.1)   
   Lymphoma   44 (7.5)   16 (4.0)   
   Immune disorder   4 (0.7)   2 (0.5)   
   Chronic leukemia   230 (39.4)   122 (30.3)   
   Other   2 (0.3)   5 (1.2)   
Stem cell source    .24  
   Bone marrow   546 (93.5)   386 (95.8)   
   Cord blood   5 (0.9)   2 (0.5)   
   Peripheral blood stem cells   33 (5.7)   15 (3.7)   
Donor type    .004  
   Related   478 (81.8)   350 (86.6)   
   Unrelated   106 (18.2)   53 (13.2)   
Conditioning regimen    .02  
   Chemotherapy   55 (9.4)   57 (14.1)   
   Radiation and chemotherapy   529 (90.6)   346 (85.9)   
cGVHD    .04  
   Yes   313 (53.6)   188 (46.7)   
   No
 
271 (46.4)
 
215 (53.3)
 

 

For participants, n = 584; for nonparticipants, n = 403

COH indicates City of Hope; and UMN, University of Minnesota

*

The mean for participants was 31.0 y (SD = 12.8 y), and the mean for nonparticipants was 25.4 y (SD = 12.6 y)

The mean for participants was 40.4 y (SD = 10.7 y), and the mean for nonparticipants was 37.0 y (SD = 10.6 y)

The mean for participants was 9.6 y (SD = 6.0 y), and the mean for nonparticipants was 11.6 y (SD = 6.3 y)

or Create an Account

Close Modal
Close Modal